The vector of anti-CD20 chimeric antigen receptor(CAR) is constructed for the engineering of NK cells to target Human CD20. The NK cells are genetically modified through transduction with a Lentiviral vector expressing scFv of anti-CD20 antibody linked to CD4 transmembrane domain and FcεRIγ signaling domains. And the vector product was designed for the treatment of chronic lymphocytic leukemia (CLL).
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
|VP-CAR-LC346||Lenti-CD20 CAR (scFv-CD4-FcεRIγ, 1F5) Viral Particle|
|CAR-T-2-M302-2Z||Anti-CD20 scFv h(CD28-CD3ζ) CART, pCDCAR1|
|CAR-MZ058||Anti-CD20 (Ofatumumab) h(41BB-CD3ζ) CAR, pCDCAR1|
|TCR-C034Z||Human anti-CD20 T cell receptor (A64), pCDTCR1|
|CAR-NK-2-M327-BZ||Anti-CD20 scFv h(41BB-CD3ζ) CARNK, pCDCAR1|
|CAR-MZ018||Anti-CD20 (Leu-16) h(CD28-4-1BB-CD3ζ) CAR, pCDCAR1|
|VP-CAR-LC769||Lenti-CD20 CAR (scFv-FcγRIII, Ofatumumab) Viral Particle|
|CAR-NK-1-M327-G||Anti-CD20 scFv h(FcεRIγ) CARNK, pCDCAR1|
|VP-TCR-C312||Lenti-CD20 T cell receptor (A94) Viral Particle|
|VP-CAR-LC343||Lenti-CD20 CAR (scFv-CD3ζ, 1F5) Viral Particle|
Copyright © 2007 - 2019 Creative Biolabs. All Rights Reserved